Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial

W. H. Liggett,John D. Hainsworth,David R. Spigel,Anthony A. Meluch,Eric Raefsky,S Kennedy,M. Thomas,Manuel Grimaldi,Ruben A. Saez,F. A. Greco

Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial

2005

W. H. Liggett
John D. Hainsworth
David R. Spigel
Anthony A. Meluch
Eric Raefsky
S Kennedy
M. Thomas
Manuel Grimaldi
Ruben A. Saez
F. A. Greco

6556 Background: The addition of rituximab to fludarabine-based chemotherapy has improved the molecular CR rate and extended progression-free survival as first-line treatment for CLL/SLL. Alemtuzum...

Keywords:

Chronic lymphocytic leukemia
Lymphocytic lymphoma
Alemtuzumab
Fludarabine rituximab
Cancer research
Medicine
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations